HOWL — Werewolf Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1785530 ·
Last close
$0.46
Market Cap
$22.51M
52W High
$1.14
52W Low
$0.40
ADV30
521,580
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -13,271,000 | -13,532,000 | 58,022,000 | 46,450,000 | 45,820,000 |
| Dec 2025 | 0 | — | -9,418,000 | -8,381,000 | 69,396,000 | 57,050,000 | 44,591,000 |
| Sep 2025 | 0 | — | -15,726,000 | -16,370,000 | 79,627,000 | 65,711,000 | 50,013,000 |
| Jun 2025 | 0 | — | -17,542,000 | -17,982,000 | 92,566,000 | 77,596,000 | 51,102,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,292,000
Investing CF
$0
Financing CF
$6,028,000
CapEx
$-126,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-475,410,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-55,548,000
Pretax Income TTM
$-60,822,000
Interest Exp TTM
$5,274,000
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -60,677,000 | -60,822,000 | 69,396,000 | 44,591,000 | — | -60,292,000 |
| Dec 2024 | 1,885,000 | -73,594,000 | -70,515,000 | 126,929,000 | 53,539,000 | — | -56,188,000 |
| Dec 2023 | 19,943,000 | -40,503,000 | -37,368,000 | 174,833,000 | 63,459,000 | — | -32,612,000 |
| Dec 2022 | 16,401,000 | -56,056,000 | -53,810,000 | 160,245,000 | 37,908,000 | — | -40,596,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$8,541,000
NetIncome TTM
$-50,659,000
OpCashFlow TTM
$0
Assets (Latest)
$126,929,000
Forward EPS
$-0.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VYNE | VYNE Therapeutics Inc. | $22.66M | $0.68 | — |
| KTTA | Pasithea Therapeutics Corp. | $22.73M | $0.68 | — |
| SNSE | Sensei Biotherapeutics, Inc. | $22.10M | $16.47 | — |
| AYTU | AYTU BIOPHARMA, INC | $23.40M | $2.18 | — |
| TRAW | Traws Pharma, Inc. | $23.94M | $1.58 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation
2026-05-14 11:23 · Yahoo
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 20:05 · Yahoo
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
2026-03-27 11:00 · Yahoo
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
2026-02-24 21:09 · Yahoo
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results
2026-01-13 14:56 · Yahoo
Werewolf Therapeutics Announces Pipeline and Business Updates
2025-12-18 13:00 · Yahoo
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
2025-12-15 17:00 · Yahoo
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
2025-11-07 14:00 · Yahoo
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-04 12:00 · Yahoo
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
2025-10-31 12:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.